Webinar: Newly-Diagnosed: What Are My Treatment Options? by Weill Cornell Medicine

Newly-Diagnosed: What Are My Treatment Options?

About

Each year, approximately 180,000 men in the U.S. receive a prostate cancer diagnosis. Detecting the presence of prostate cancer in the body is just the beginning, especially since disease aggressiveness can vary widely. Join the experts for an important conversation on how to navigate different prostate cancer treatment options, from active surveillance to radiation therapy, surgery, focal therapy, and beyond.

Presenters

Christopher Anderson, MD

Christopher Anderson, MD, is an Assistant Professor of Urology at Columbia University Medical Center (CUMC). Dr. Anderson joined the Department of Urology in September 2015. He specializes in cancers of the bladder, prostate, kidney, testis and penis and performs both open and robotic surgeries. Dr. Anderson completed his medical degree from Northwestern University, and then completed his urology residency at Vanderbilt University. Following his residency, Dr. Anderson completed a urologic oncology fellowship at Memorial Sloan Kettering Cancer Center and obtained a Master of Public Health degree from Harvard University.

Dr. Anderson's research interests include factors that influence the quality of surgery, access to care for patients with bladder cancer, outcomes after robotic prostatectomy, and active surveillance strategies for men with prostate cancer. Dr. Anderson has published several peer-reviewed articles and was recognized as "Best Reviewer" in 2014 by The Journal of Urology and in 2016 by Cancer.

Dr. Anderson has clinical expertise in robotic prostatectomy for the treatment of prostate cancer, radical cystectomy with orthotopic neobladder for patients with bladder cancer, and partial nephrectomy for the treatment of kidney tumors. He also specializes in the multidisciplinary management of men with testicular cancer, including the use of primary and post-chemotherapy retroperitoneal lymph node dissection. He is currently the site leader for several clinical trials investigating the use of immunotherapy in patients with invasive and non-invasive bladder cancer.

Jonathan Coleman, MD

Jonathan Coleman, MD is a urologic surgeon with expertise in minimally invasive techniques for the treatment of kidney, adrenal, and prostate cancers. Using laparoscopic, robotic, and image-guided therapies, the goal of the urology team is to provide appropriate curative therapeutic interventions through the organ-sparing approaches of less-invasive surgery. Dr. Coleman is interested in the application and careful study of techniques such as robotic (da Vinci) prostatectomy, laparoscopic partial nephrectomy, partial adrenalectomy, cryo- and radiofrequency ablation, and MRI-guided prostate interventions using state-of-the-art instrumentation and imaging technology. These surgical approaches are coupled with basic science research investigations of human cancers to discover optimal therapeutic strategies that can be tailored to each of our patients. Additionally, Dr. Coleman has a special interest in patients with hereditary urologic cancer syndromes, including von Hipple-Lindau, Birt-Hogg-Dube, hereditary papillary kidney cancer, and hereditary leiomyomatosis and renal cell cancer.

Himanshu Nagar, MD

Dr. Himanshu Nagar is Assistant Professor of Radiation Oncology at NewYork-Presbyterian/Weill Cornell Medicine. He is a recognized expert specializing in treating men with prostate cancer. Dr. Nagar leads several investigator-initiated trials at Weill Cornell Medicine and nationally. He has a particular interest in advanced imaging modalities for treating prostate cancer and defining imaging and molecular biomarkers for treatment response and resistance.

David Nanus, MD

Dr. David Nanus is an internationally recognized leader in the treatment and care of patients with genitourinary (GU) cancers, including cancers of the prostate, kidney, bladder and testes. He is actively involved in clinical, translational and basic research in GU malignancies, serving as principle or co-investigator on a variety of clinical research trials that incorporate novel targeted therapies for his patients. Dr. Nanus is Director of the NewYork-Presbyterian and Weill Cornell Medicine Healthcare Services Cancer Program, a program unifying oncology and hematology clinical care and research at NewYork-Presbyterian’s regional hospitals. He previously served as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian.

Douglas Scherr, MD

Dr. Douglas Scherr is the Clinical Director of Urologic Oncology and Professor of Urology at the Weill Medical College of Cornell University. Dr. Scherr’s clinical focus is in the treatment of urologic malignancies – in particular, the treatment of prostate cancer, bladder cancer, kidney cancer and testicular cancers, as well as genitourinary and retroperitoneal sarcomas. Dr. Scherr was the first physician at Cornell to perform a robotic prostatectomy, and he has since performed thousands of these procedures and travels nationally and internationally teaching the procedure to many urologic surgeons.

Susan Slovin, MD, PhD

Dr. Susan Slovin is an Attending Physician in the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and a Professor of Medicine at Weill Cornell Medical College. She is a board-certified medical oncologist with expertise in the areas of prostate cancer immunology and clinical trial design. A noted immunologist, she leads an initiative that focuses on the development of novel immunologic approaches for the treatment of prostate cancer. This includes assuming leadership of the Prostate Immunotherapy Group, sponsored by the Prostate Cancer Foundation, whose challenge is to develop guidelines for development of immune therapy clinical trials in prostate cancer.

Mark Stein, MD

Dr. Mark Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in the field of genitourinary oncology, treating patients with prostate, kidney, bladder and testicular cancers. In addition to providing standard therapies for the treatment of genitourinary cancers, such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator-initiated and industry-sponsored clinical trials. He has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer, as well as in men with advanced prostate cancer.